Name | 5-O-(oxan-2-ylmethyl) 3-O-[2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)ethyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
---|---|
Synonyms | PCA50941 |
Description | PCA50941 is a 1,4-dihydropyridine derivative, used for treatment for cardiovascular disease. |
---|---|
Related Catalog | |
In Vitro | PCA50941 (1 μM) shifts the I-V relationship of whole-cell Ca2+ currents by about 5-10 mV towards more hyperpolarizing potentials. PCA50941 increases further the K(+)-evoked peak to 655 nM. In the presence of 5 mM Ca2+, PCA50941 increases the [Ca2+] peaks to 427 nM. PCA50941 potentiates the release of catecholamines from perfused bovine adrenal glands evoked by 30 s pulses of 17.7 mM K+ in a manner dependent on the [Ca2+]o[1]. |
In Vivo | PCA50941 (10-120 μM) by intracoronary injection, causes smaller reductions of coronary blood flow (CBF) in goats. PCA50941 (10-300 μM/min) does not modify CBF nor the other hemodynamic variables recorded by i.v. infusions in 4 goats. Intravenous infusion of PCA50941 (100 microg/min) reverses the hemodynamic variables from the shock state to control values within 20 min in 5 of 6 animals[2]. |
References |
Density | 1.387g/cm3 |
---|---|
Boiling Point | 816.6ºC at 760 mmHg |
Molecular Formula | C30H31N3O10S |
Molecular Weight | 625.64600 |
Flash Point | 447.7ºC |
Exact Mass | 625.17300 |
PSA | 182.51000 |
LogP | 5.20050 |
Vapour Pressure | 9.39E-27mmHg at 25°C |
Index of Refraction | 1.605 |
Storage condition | 2-8℃ |